The cognitive impact of antiepileptic drugs

Therapeutic Advances in Neurological Disorders

Volumn 4, Issue 6, 2011, Pages 385-407

  Eddy, Clare M ^a   Rickards, Hugh E ^a   Cavanna, Andrea E ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antiepileptic drugs; cognition; epilepsy; medication; neuropsychology; seizure

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ALERTNESS; AMNESIA; ATTENTION; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; COGNITION; COGNITIVE DEFECT; COORDINATION; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; EPILEPSY; EXECUTIVE FUNCTION; FLUENCY DISORDER; FOCAL EPILEPSY; HUMAN; IMPULSIVENESS; INTELLIGENCE QUOTIENT; LANGUAGE DISABILITY; LONGITUDINAL STUDY; LOW DRUG DOSE; MEMORY; MEMORY DISORDER; METHODOLOGY; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROPSYCHOLOGY; PARKINSONISM; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR DISORDER; REACTION TIME; REVIEW; SELECTIVE ATTENTION; SHORT TERM MEMORY; SIDE EFFECT; TASK PERFORMANCE; VERBAL MEMORY; VISUAL ANALOG SCALE; VISUAL MEMORY; WORKING MEMORY;

EID: 82955164019     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611417920     Document Type: Article

References (156)

1. Aikiä M. Jutila L. Salmenperä T. Mervaala E. Kälviäinen R. (2006) Long-term effects of tiagabine monotherapy on cognition and mood in adult patients with chronic partial epilepsy. Epilepsy Behav 8: 750–755.
2. Aikiä M. Kälviäinen R. Sivenius J. Halonen T. Riekkinen P.J. (1992) Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 11: 199–203.
3. Aldenkamp A.P. Alpherts W.C. Moerland M.C. Ottevanger N. van Parys J.A. (1987) Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia 28: 507–514.
4. Aldenkamp A.P. Alpherts W.C.J. Diepman L. Vantslot B. Overweg J. Vermeulen J. (1994) Cognitive side-effects of phenytoin compared with carbamazepine in patients with localization related epilepsy. Epilepsy Res 19: 37–43.
5. Aldenkamp A.P. Baker G. Mulder O.G. Chadwick D. Cooper P. Doelman J. et al. (2000) A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 41: 1167–1178.
6. Aldenkamp A.P. Mulder O.G. Overweg J. (1997) Cognitive effects of lamotrigine as first-line add-on in patients with localization-related (partial) epilepsy. J Epilepsy 10: 117–121.
7. Aman M.G. Werry J.S. Paxton J.W. Turbott S.H. (1994) Effects of phenytoin on cognitive-motor performance in children as a function of drug concentration, seizure type, and time of medication. Epilepsia 35: 172–180.
8. Andrewes D.G. Bullen J.G. Tomlinson L. Elwes R.D. Reynolds E.H. (1986) A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy. Epilepsia 27: 128–134.
9. Arroyo S. Anhut H. Kugler A.R. Lee C.M. Knapp L.E. Garofalo E.A. et al. (2004) Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45: 20–27.
10. Arroyo S. Dodson W.E. Privitera M.D. Glauser T.A. Naritoku D.K. Dlugos D.J. et al. (2005) Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 112: 214–222.
11. Baker G.A. Currie N.G. Light M.J. Schneiderman J.H. (2002) The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsy-a Canadian study. Seizure 11: 6–15.
12. Banks G.K. Beran R.G. (1991) Neuropsychological assessment in lamotrigine treated epileptic patients. Clin Exp Neurol 28: 230–237.
13. Bawden H.N. and the Canadian Study Group for childhood Epilepsy. (1999) The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Epilepsy Res 33: 133–143.
14. Berent S. Sackellares J.C. Giordani B. Wagner J.G. Donofrio P.D. Abou-Khalil B. (1987). Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 28: 61–67.
15. Beydoun A. Uthman B.M. Kugler A.R. Greiner M.J. Knapp L.E. Garofalo E.A. (2005) Safety and efficacy of two pregabalin regimens for partial epilepsy: An add-on, placebo-controlled trial. Neurology 64: 475–480.
16. Bishop M. Allen C.A. (2003) The impact of epilepsy on quality of life: a qualitative analysis. Epilepsy Behav 4: 226–233.
17. Bittencourt P.R. Antoniuk S.A. Bigarella M.M. da Costa J.C. Doro M.P. Ferreira A.S. et al. (1993) Carbamazepine and phenytoin in epilepsies refractory to barbiturates: efficacy, toxicity and mental function. Epilepsy Res 16: 147–155.
18. Blum D. Meador K. Biton V. Fakhoury T. Shneker B. Chung S. et al. (2006) Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 67: 400–406.
19. Bootsma H.P. Aldenkamp A.P. Diepman L. Hulsman J. Lambrechts D. Leenen L. et al. (2006) The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. Epilepsia 47(Suppl. 2): 24–27.
20. Bootsma H.P. Ricker L. Hekster Y.A. Hulsman J. Lambrechts D. Majoie M. et al. (2009) The impact of side effects on long term retention in three new antiepileptic drugs. Seizure 18: 327–331.
21. Bootsma H.P.R. Ricker L. Diepman L. Gehring J. Hulsman J. Lambrechts D. et al. (2008 a) Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison. Seizure 17: 19–26.
22. Bootsma H.P.R. Vos A.M. Hulsman J. Lambrechts D. Leenen L. Majoie M. et al. (2008 b) Lamotrigine in clinical practice: Long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 12: 262–268.
23. Brandl U. Kurlemann G. Neubauer B. Rettig K. Schauble B. Schreiner A. (2010) Seizure and cognitive outcomes in children and adolescents with epilepsy treated with topiramate. Neuropediatrics 41: 113–120.
24. Brouwer O.F. Pieters M.S. Edelbroek P.M. Bakker A.M. van Geel A.A. Stijnen T. et al. (1992) Conventional and controlled release valproate in children with epilepsy: a cross-over study comparing plasma levels and cognitive performances. Epilepsy Res 13: 245–253.
25. Browne T.R. Dreifuss F.E. Dyken P.R. Goode D.J. Penry J.K. Porter R.J. et al. (1975) Ethosuximide in the treatment of absence (petit mal) seizures. Neurology 25: 515–524.
26. Calandre E.P. Dominguez-Granados R. Gomez-Rubio M. Molina-Font J.A. (1990) Cognitive effects of long-term treatment with phenobarbital and valproic acid in school children. Acta Neurologica Scand 81: 504–506.
27. Camfield C.S. Chaplin S. Doyle A.B. Shapiro S.H. Cummings C. Camfield P.R. (1979) Side effects of phenobarbital in toddlers; behavioural and cognitive aspects. J Pediatr 95: 361–365.
28. Camposano S.E. Major P. Halpern E. Thiele E.A. (2008) Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia 49: 1186–1191.
29. Capovilla G. Beccaria F. Veggiotti P. Rubboli G. Meletti S. Tassinari C.A. (1999) Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy. J Child Neurol 14: 395–400.
30. Chung S. Wang N. Hank N. (2007) Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 16: 296–304.
31. Ciesielski A.S. Samson S. Steinhoff B.J. (2006) Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study. Epilepsy Behav 9: 424–431.
32. Coenen A.M.L. Konings G.M.L.G. Aldenkamp A.P. Reiner W.O. van Luijtelaar E.L.J.M. (1995) Effects of chronic use of carbamazepine and valproate on cognitive processes. J Epilepsy 8: 250–254.
33. Coppola G. Caliendo G. Veggiotti P. Romeo A. Tortorella G. de Marco P. et al. (2002) Topiramate as add-on drug in children, adolescents and young adults with Lennox–Gastaut syndrome: an Italian multicentric study. Epilepsy Res 51: 147–153.
34. Coppola G. Verrotti A. Resicato G. Ferrarelli S. Auricchio G. Operto F.F. Pascotto A. (2008) Topiramate in children and adolescents with epilepsy and mental retardation: a prospective study on behavior and cognitive effects. Epilepsy Behav 12: 253–256.
35. Craig I. Tallis R. (1994) Impact of valproate and phenytoin on cognitive function in elderly patients – results of a single-blind randomized comparative study. Epilepsia 35: 381–390.
36. Cramer J. Ryan J. Chang J. Sommerville K. (2001) The short-term impact of adjunctive tiagabine on health-related quality of life. Epilepsia 42(Suppl. 3): 70–75.
37. Cramer J.A. Arrigo C. van Hammee G. Gauer L.J. Cereghino J.J. (2000) Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 41: 868–874.
38. de Araujo Filhou G.M. Pascalicchio T.F. Lin K. Sousa P.S. Yacubian E.M. (2006) Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate. Epilepsy Behav 8: 606–609.
39. Dean C. Mosier M. Penry K. (1999) Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 40: 74–82.
40. Dodrill C.B. Arnett J.L. Deaton R. Lenz G.T. Sommerville K.W. (2000) Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood. Epilepsy Res 42: 123–132.
41. Dodrill C.B. Arnett J.L. Hayes A.G. Garofalo E.A. Greeley C.A. Greiner M.J. et al. (1999) Cognitive abilities and adjustment with gabapentin: results of a multisite study. Epilepsy Res 35: 109–121.
42. Dodrill C.B. Arnett J.L. Shu V. Pixton G.C. Lenz G.T. Sommerville K.W. (1998) Effects of tiagabine on abilities, adjustment and mood. Epilepsia 39: 33–42.
43. Dodrill C.B. Arnett J.L. Sommerville K.W. Shu V. (1997) Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 48: 1025–1031.
44. Dodrill C.B. Arnett J.L. Sommerville K.W. Sussman N.M. (1993) Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology 43: 2501–2507.
45. Donati F. Gobbi G. Campistol J. Rapatz G. Daehler M. Sturm Y. et al. (2006) Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. Neurology 67: 679–682.
46. Donati F. Gobbi G. Campistol J. Rapatz G. Daehler M. Sturm Y. et al. (2007) The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures. Seizure 16: 670–679.
47. Duncan J.S. Shorvon S.D. Trimble M.R. (1990) Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia 31: 584–591.
48. Engelberts N.H. Klein M. van der Ploeg H.M. Heimans J.J. Jolles J. Kasteleijn-Nolst Trenité D.G. (2002) Cognition and health-related quality of life in chronic well-controlled patients with partial epilepsy on carbamazepine monotherapy. Epilepsy Behav 3: 316–321.
49. Farwell J.R. Lee Y.J. Hirtz D.G. Sulzbacher S.I. Ellenberg J.H. Nelson K.B. (1990) Phenobarbital for febrile seizures: effects on intelligence and on seizure recurrence. New Engl J Med 322: 364–369.
50. Forsythe I. Butler R. Berg I. McGuire R. (1991) Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol 33: 524–534.
51. French J.A. Kugler A.R. Robbins J.L. Knapp L.E. Garofalo E.A. (2003) Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60: 1631–1637.
52. Fritz N. Glogau S. Hoffmann J. Rademacher M. Elger C.E. Helmstaedter C. (2005) Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 6: 373–381.
53. Froscher W. Schier K.R. Hoffmann M. Meyer A. May T.W. Rambeck B. et al. (2005) Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord 7: 237–248.
54. Galassi R. Morreale A. Lorusso S. Procaccianti G. Lugaresi E. Baruzzi A. (1990) Cognitive effects of valproate. Epilepsy Res 5: 160–164.
55. Gerber P.E. Hamiwka L. Connolly M.B. Farrell K. (2000). Factors associated with behavioral and cognitive abnormalities in children receiving topiramate. Pediatr Neurol 22: 200–203.
56. Gigli G.L. Maschio M. Diomedi M. Placidi F. Silvestri G. Marciani M.G. (1996) Cognitive performances in newly referred patients with temporal lobe epilepsy: comparison with normal subjects in basal condition and after treatment with controlled-release carbamazepine. Int J Neurosci 88: 97–107.
57. Gillham R. Kane K. Bryant-Comstock L. Brodie M.J. (2000) A double blind comparison on lamotrigine and carbamazepine in newly diagnosed epilepsy with quality of life as an outcome measure. Seizure 9: 375–379.
58. Gillham R.A. Blacklaw J. McKee P.J.W. Brodie M.J. (1993) Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. J Neurol Neurosurg Psychiatr 56: 1271–1275.
59. Gillham R.A. Read C.L. McKee P.J.M. Larkin J.G. Brodie M.J. (1991) Cognitive function in epileptic patients on long-term sodium valproate. J Epilepsy 4: 205–210.
60. Gillham R.A. Williams N. Wiedmann K.D. Butler E. Larkin J.G. Brodie M.J. (1988) Concentration–effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. J Neurol Neurosurg Psychiatr 51: 929–933.
61. Gillham R.A. Williams N. Wiedmann K.D. Butler E. Larkin J.G. Brodie M.J. (1990) Cognitive function in adult epileptic patients established on anticonvulsant monotherapy. Epilepsy Res 7: 219–225.
62. Glauser T.A. Cnaan A. Shinnar S. Hirtz D.G. Dlugos D. Masur D. et al. (2010) Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 362: 790–799.
63. Gomer B. Wagner K. Frings L. Saar J. Carius A. Härle M. et al. (2007) The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 10: 486–494.
64. Gonzalez P.A. McCall A. McQuistan A. Keating D. Brodie M.J. Parks S. (2006) Assessing retinal toxicity of vigabatrin and other gaga-ergic drugs in patients with epilepsy. Assoc Res Vision Ophthalmol 1658: B521.
65. Grunewald R.A. Thompson P.J. Cocoran R. Corden Z. Jackson G.D. Duncan J.S. (1994) Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatr 57: 1057–1063.
66. Guberman A. Bruni J. (2000) Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. Seizure 9: 112–118.
67. Helmstaedter C. Fritz N.E. Kockelmann E. Kosanetzky N. Elger C.E. (2008) Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav 13: 535–541.
68. Helmstaedter C. Witt J.A. (2010) Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: A non-interventional surveillance trial. Epilepsy Behav 18: 74–80.
69. Hessen E. Lossius M.I. Gjerstad L. (2009) Antiepileptic monotherapy significantly impairs normative scores on common tests of executive functions. Acta Neurol Scand 119: 194–198.
70. Hessen E. Lossius M.I. Reinvang I. Gjerstad L. (2006) Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia 47: 2038–2045.
71. Huang C.-W. Pai M.-C. Tsai J.-J. (2008) Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy. Psychiatr Clin Neurosci 62: 548–553.
72. Jan M.M. Shaabat A.O. (2000) Clobazam for the treatment of intractable childhood epilepsy. Saudi Med J 21: 622–624.
73. Jan M.M. Zuberi S.A. Alsaihati B.A. (2009) Pregabalin: preliminary experience in intractable childhood epilepsy. Pediatr Neurol 40: 347–350.
74. Jung J.-Y. Cho J.-W. Joo E.Y. Kim S.H. Choi K.M. Chin J. et al. (2010) Cognitive effects of topiramate revealed by standardised low-resolution brain electromagnetic tomography (sLORETA) of event-related potentials. Clin Neurophysiol 121: 1494–1501.
75. Kälviäinen R. Aikiä M. Mervaala E. Saukkonen A.M. Pitkänen A. Riekkinen P.J. Sr (1996) Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res 25: 291–297.
76. Kälviäinen R. Aikiä M. Saukkonen A.M. Mervaala E. Riekkinen P.J. Sr (1995) Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 52: 989–996.
77. Kang H.C. Eun B.L. Wu Lee C. Ku Moon H. Kim J.S. Wook Kim D. et al. (2007) Korean Pediatric Topiramate Study Group. The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia 48: 1716–1723.
78. Kanner A.M. Wuu J. Faught E. Tatum W.O. IV Fix A. French J.A. (2003) A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4: 548–552.
79. Kim H.L. Aldridge J. Rho J.M. (2005) Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol 20: 212–219.
80. Kim S.Y. Lee H.W. Jung D.K. Suh C.K. Park S.P. (2006) Cognitive effects of low-dose topiramate compared with oxcarbazepine in epilepsy patients. J Clin Neurol 2: 126–133.
81. Kockelmann E. Elger C.E. Helmstaedter C. (2003) Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res 54: 171–178.
82. Kockelmann E. Elger C.E. Helmstaedter C. (2004) Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. Epilepsy Behav 5: 716–721.
83. Kothare S.V. Kaleyias J. Mostofi N. Valencia I. Melvin J.J. Hobdell E. (2006) Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr Neurol 34: 351–354.
84. Larkin J.G. McKee P.J.W. Brodie M.J. (1992) Rapid tolerance to acute psychomotor impairment with carbamazepine in epileptic patients. Br J Clin Pharmacol 33: 111–114.
85. Leach J.P. Girvan J. Paul A. Brodie M.J. (1997) Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatr 62: 372–376.
86. Lee H.W. Jung D.K. Suh C.K. Kwon S.H. Park S.P. (2006) Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: A 1-year follow-up. Epilepsy Behav 8: 736–741.
87. Lee S. Sziklas V. Andermann F. Farnham S. Risse G. Gustafson M. et al. (2003) The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 44: 339–347.
88. Lee S.A. Lee H.W. Heo K. Shin D.J. Song H.K. Kim O.J. et al. (2011) Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure 20: 49–54.
89. Levisohn P.M. Mintz M. Hunter S.J. Yang H.C. Jones J. (2009) Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: A randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia 50: 2377–2389.
90. Lippa C.F. Rosso A. Hepler M. Jenssen S. Pillai J. Irwin D. (2010) Levetiracetam: A practical option for seizure management in elderly patients with cognitive impairment. Am J Alzheimers Dis Other Demen 25: 149–154.
91. López-Góngora M. Martínez-Domeño A. García C. Escartín A. (2008) Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study. Epileptic Disord 10: 297–305.
92. Majkowski J. Neto W. Wapenaar R. van Oene J. (2005) Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine. Epilepsia 46: 648–653.
93. Manni R. Ratti M.T. Perruca E. Galimberti C.A. Tartara A. (1993) A multiparametric investigation of daytime sleepiness and psychomotor functions in patients treated with phenobarbital and sodium valproate – a comparative controlled study. Electroencephalogr Clin Neurophysiol 86: 322–328.
94. Marciani M.G. Stanzione P. Mattia D. Spanedda F. Bassetti M.A. Maschio M. et al. (1998) Lamotrigine add-on therapy in focal epilepsy: electroencephalographic and neuropsychological evaluation. Clin Neuropharmacol 21: 41–47.
95. May T.W. Bulmahn A. Wohlhuter M. Rambeck B. (1992) Effects of withdrawal of phenytoin on cognitive and psychomotor functions in hospitalized epileptic patients on polytherapy. Acta Neurol Scand 86: 165–170.
96. McGuire A.M. Duncan J.S. Trimble M.R. (1992) Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia 33: 128–134.
97. McKee P.J. Blacklaw J. Forrest G. Gillham R.A. Walker S.M. Connelly D. et al. (1994) A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 37: 27–32.
98. McKee P.J.W. Blacklaw J. Butler E. Gillham R.A. Brodie M.J. (1992) Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res 11: 193–198.
99. Meador K.J. Loring D.W. Hulihan J.F. Kamin M. Karim R. (2003) Differential cognitive and behavioural effects of topiramate and valproate. Neurology 60: 1483–1488.
100. Meador K.J. Loring D.W. Ray P.G. Murrow A.M. King D.W. Nichols M.E. et al. (1999) Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 40: 1279–1285.
101. Mohamed K. Appleton R. Rosenbloom L. (2000) Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure 9: 137–141.
102. Monaco F. Torta R. Cicolin A. Borio R. Varetto A. Bergamasco L. et al. (1997) Lack of association between vigabatrin and impaired cognition. J Int Med Res 25: 296–301.
103. Montenegro M.A. Cendes F. Noronha A.L.A. Mory S.B. Carvalho M.I. Marques L.H.N. et al. (2001) Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia 42: 539–542.
104. Moreland E.C. Griesemer D.A. Holden K.R. (1999) Topiramate for intractable childhood epilepsy. Seizure 8: 38–40.
105. Mortimore C. Trimble M. Emmers E. (1998) Effects of gabapentin on cognition and quality of life in patients with epilepsy. Seizure 7: 359–364.
106. Mula M. Trimble M.R. Sander J.W. (2003 a) The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia 44: 1573.
107. Mula M. Trimble M.R. Thompson P. Sander J.W. (2003 b) Topiramate and word-finding difficulties in patients with epilepsy. Neurology 60: 1104–1107.
108. Munn R. Farrell K. (1993) Open study of clobazam in refractory epilepsy. Pediatric Neurol 9: 465–469.
109. Naili F. Boucart M. Derambure P. Arndt C. (2009) Visual impairment at large eccentricity in participants treated by vigabatrin: visual, attentional or recognition deficit?. Epilepsy Res 87: 213–222.
110. Neyens L.G.J. Alpherts W.C.J. Aldenkamp A.P. (1995) Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatr 19: 411–419.
111. O'Dougherty M. Wright F.S. Cox S. Walson P. (1987) Carbamazepine plasma concentration. Relationship to cognitive impairment. Arch Neurol 44: 863–867.
112. Park S.P. Hwang Y.H. Lee H.W. Suh C.K. Kwon S.H. Lee B.I. (1999) Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 12: 102–108.
113. Park S.P. Kim S.Y. Hwang Y.H. Lee H.W. Suh C.K. Kwon S.H. (2007) Long-term efficacy and safety of zonisamide monotherapy in epilepsy patients. J Clin Neurol 3: 175–180.
114. Piazzini A. Chifari R. Canevini M.P. Turner K. Fontana S.P. Canger R. (2006) Levetiracetam: An improvement of attention and of oral fluency in patients with partial epilepsy. Epilepsy Res 68: 181–188.
115. Pieters M.S. van Steveninck A.F. Schoemaker R.C. Kroon J.M. van Gerven J.M. Cohen A.F. (2003) The psychomotor effects of carbamazepine in epileptic patients and healthy volunteers. J Psychopharmacol 17: 269–272.
116. Placidi F. Marciani M.G. Diomedi M. Scalise A. Pauri F. Giacomini P. et al. (2000) Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy. Acta Neurol Scand 102: 81–86.
117. Pressler R.M. Binnie C.D. Coleshill S.G. Chorley G.A. Robinson R.O. (2006) Effect of lamotrigine on cognition in children with epilepsy. Neurology 66: 1495–1499.
118. Prevey M.L. Delaney R.C. Cramer J.A. Cattanach L. Collins J.F. Mattson H. (1996) Effect of valproate on cognitive functioning: comparison with carbamazepine. Arch Neurol 53: 1008–1016.
119. Provinciali L. Bartolini M. Mari F. Del Pesce M. Ceravolo M.G. (1996) Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy. Acta Neurol Scand 94: 12–18.
120. Pulliainen V. Jokelainen M. (1994) Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients. Acta Neurol Scand 89: 81–86.
121. Pulliainen V. Jokelainen M. (1995) Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two-year follow-up. Epilepsia 36: 1195–1202.
122. Ramsay R.E. Uthman B. Pryor F.M. Rowan A.J. Bainbridge J. Spitz M. et al. (2008) Topiramate in older patients with partial-onset seizures: A pilot double-blind, dose-comparison study. Epilepsia 49: 1180–1185.
123. Reith D. Burke C. Appleton D.B. Wallace G. Pelekanos J. (2003) Tolerability of topiramate in children and adolescents. J Paediatr Child Health 39: 416–419.
124. Ristic A.J. Vojvodic N. Jankovic S. Sindelic A. Sokic D. (2006) The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: A study of 364 patients with different types of epilepsy. Epilepsia 47: 2183–2185.
125. Riva D. Devoti M. (1996) Discontinuation of phenobarbital in children: Effects on neurocognitive behaviour. Pediatr Neurol 14: 36–40.
126. Riva D. Devoti M. (1999) Carbamazepine withdrawal in children with previous symptomatic partial epilepsy: Effects on neuropsychologic function. J Child Neurol 14: 357–362.
127. Rodin E.A. Rim C.S. Kitano H. Lewis R. Rennick P.M. (1976) A comparison of the effectiveness of primidone versus carbamazepine in epileptic outpatients. J Nerv Ment Dis 163: 41–46.
128. Rosche J. Uhlmann C. Weber R. Froscher W. (2004) Different cognitive effects of inducing levetiracetam or topiramate into an antiepileptic pharmacotherapy in patients with therapy refractory epilepsy. Neurol Psychiatr Brain Res 11: 109–114.
129. Rosenfeld W.E. Liao S. Kramer L.D. Anderson G. Palmer M. Levy R.H. et al. (1997) Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 38: 324–333.
130. Seidel W.T. Mitchell W.G. (1999) Cognitive and behavioral effects of carbamazepine in children: data from benign rolandic epilepsy. J Child Neurol 14: 716–723.
131. Seo J.G. Lee D.I. Hwang Y.H. Lee H.W. Jung D.K. Suh C.K. et al. (2007) Comparison of cognitive effects of lamotrigine and oxcarbazepine in epilepsy patients. J Clin Neurol 3: 31–37.
132. Shehata G.A. Bateh Ael A. Hamed S.A. Rageh T.A. Elsorogy Y.B. (2009) Neuropsychological effects of antiepileptic drugs (carbamazepine versus valproate) in adult males with epilepsy. Neuropsychiatr Dis Treat 5: 527–533.
133. Smith D. Baker G. Davies G. Dewey M. Chadwick D.W. (1993) Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 34: 312–322.
134. Smith D.B. Mattson R.H. Cramer J.A. Collins J.F. Novelly R.A. Craft B. (1987) Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 28: S50–S58.
135. Spitz M.C. Deasy D.N. (1991) Conversion to sodium valproate in nonretarded adults with primary generalized tonic clonic seizures. J Epilepsy 4: 33–38.
136. Stores G. Williams P.L. Styles E. Zaiwalla Z. (1992) Psychological effects of sodium valproate and carbamazepine in epilepsy. Arch Dis Child 67: 1330–1337.
137. Sudhir R.V.R. Sawhney I.M.S. Prabhakar S. Pershad D. Nain C.K. (1995) Comparative cognitive effects of phenytoin and carbamazepine in adult epileptics. Neurology India 43: 186–192.
138. Sun W. Wang Y. Wang W. Wu X. (2008) Attention changes in epilepsy patients following 3-month topiramate or valproate treatment revealed by event-related potential. Int J Psychophysiol 68: 235–241.
139. Sveinbjornsdottir S. Sander J.W. Patsalos P.N. Upton D. Thompson P.J. Duncan J.S. (1994) Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 3: 29–35.
140. Tatum W.O. IV French J.A. Faught E. Morris G.L. III Liporace J. Kanner A. et al. (2001) Post-marketing antiepileptic drug survey. Postmarketing experience with topiramate and cognition. Epilepsia 42: 1134–1140.
141. Thompson P.J. Baxendale S.A. Duncan J.S. Sander J.W.A.S. (2000) Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 69: 636–641.
142. Tonekaboni S.H. Beyraghi N. Tahbaz H.S. Bahreynian S.A. Ashamohammadpoor M. (2006) Neurocognitive effects of phenobarbital discontinuation in epileptic children. Epilepsy Behav 8: 145–148.
143. Tzitiridou M. Panou T. Ramantani G. Kambas A. Spyroglou K. Panteliadis C. (2005) Oxcarbazepine monotherapy in benign childhood epilepsy with centrotemporal spikes: a clinical and cognitive evaluation. Epilepsy Behav 7: 458–467.
144. Valentin A. Moran N. Hadden R. Oakes A. Elwes R. Delamont R. et al. (2009) Pregabalin as adjunctive therapy for partial epilepsy: An audit study in 96 patients from the South East of England. Seizure 18: 450–452.
145. Vanhatalo S. Nousiainen I. Eriksson K. Rantala H. Vainionpaa L. Mustonen K. et al. (2002) Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 43: 748–756.
146. Veggiotti P. de Agostini G. Muzio C. Termine C. Baldi P.L. Ferrari Ginevra O. et al. (1999) Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study. Acta Neurologica Scand 99: 142–146.
147. Vining E.P.G. Mellits E.D. Dorsen M.M. Cataldo M.F. Quaskey S.A. Spielberg S.P. et al. (1987) Psychologic and behavioural effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 80: 165–174.
148. von Stülpnagel C. Kluger G. Leiz S. Holthausen H. (2010) Levetiracetam as add-on therapy in different subgroups of “benign” idiopathic focal epilepsies in childhood. Epilepsy Behav 17: 193–198.
149. Wang W.Z. Wu J.Z. Ma G.Y. Dai X.Y. Yang B. Wang T.P. et al. (2006) Efficacy assessment of phenobarbital in epilepsy: a large community-based intervention trial in rural China. Lancet Neurol 5: 46–52.
150. Wesnes K.A. Edgar C. Dean A.D.P. Wroe S.J. (2009) The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. Epilepsy Behav 14: 522–528.
151. Wheless J.W. Ng Y.T. (2002) Levetiracetam in refractory pediatric epilepsy. J Child Neurol 17: 413–415.
152. White J.R. Walczak T.S. Marino S.E. Beniak T.E. Leppik I.E. Birnbaum A.K. (2010) Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology 75: 513–518.
153. Wu T. Chen C.C. Chen T.C. Tseng Y.F. Chiang C.B. Hung C.C. et al. (2009) Clinical efficacy and cognitive and neuropsychological effects of levetiracetam in epilepsy: an open-label multicenter study. Epilepsy Behav 16: 468–474.
154. Ylinen A. (1998) Antiepileptic efficacy of vigabatrin in people with severe epilepsy and intellectual disability. J Intellect Disability Res 42(Suppl): 46–49.
155. Ylinen A. Kälviäinen R. Riekkinen P.J. (1995) Long term efficacy and cognitive effects of vigabatrin. Acta Neurol Scand 92(Suppl. 162): 47–50.
156. Zhou B. Zhang Q. Tian L. Xiao J. Stefan H. Zhou D. (2008) Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav 12: 305–310.